A disease progression model comparing the long-term mobility and respiratory outcomes of adults with late-onset Pompe disease receiving cipaglucosidase alfa plus miglustat versus alglucosidase alfa
Amy Dymond, Will Green, Matthew Crabtree, Alasdair MacCulloch et autres
0 citationsJournal of Comparative Effectiveness Research